Paul Bergmans

2.8k total citations
68 papers, 2.2k citations indexed

About

Paul Bergmans is a scholar working on Psychiatry and Mental health, Neurology and Immunology. According to data from OpenAlex, Paul Bergmans has authored 68 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Psychiatry and Mental health, 19 papers in Neurology and 19 papers in Immunology. Recurrent topics in Paul Bergmans's work include Schizophrenia research and treatment (19 papers), Psoriasis: Treatment and Pathogenesis (18 papers) and Parkinson's Disease Mechanisms and Treatments (17 papers). Paul Bergmans is often cited by papers focused on Schizophrenia research and treatment (19 papers), Psoriasis: Treatment and Pathogenesis (18 papers) and Parkinson's Disease Mechanisms and Treatments (17 papers). Paul Bergmans collaborates with scholars based in Netherlands, France and Italy. Paul Bergmans's co-authors include Erik Ch. Wolters, Jan Booij, Gerrit Tissingh, J.C. Stoof, Ania Winogrodzka, Henk W. Berendse, E.Ch. Wolters, Eric A. van Royen, Michaël Kuiper and Johannes C. Stoof and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Annals of Neurology.

In The Last Decade

Paul Bergmans

65 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Bergmans Netherlands	24	949	592	438	274	244	68	2.2k
Mamoru Shibata Japan	26	494 0.5×	528 0.9×	546 1.2×	177 0.6×	536 2.2×	90	2.5k
Hortensia Alonso‐Navarro Spain	29	1.4k 1.5×	322 0.5×	552 1.3×	40 0.1×	295 1.2×	148	2.6k
Dirk Woitalla Germany	32	2.3k 2.4×	258 0.4×	993 2.3×	107 0.4×	556 2.3×	112	3.8k
Han Soo Yoo South Korea	30	1.0k 1.1×	345 0.6×	352 0.8×	106 0.4×	507 2.1×	127	2.5k
Carlos Roberto de Mello Rieder Brazil	30	1.3k 1.4×	353 0.6×	635 1.4×	40 0.1×	280 1.1×	130	2.5k
Danna Jennings United States	33	1.8k 1.9×	584 1.0×	720 1.6×	176 0.6×	738 3.0×	81	3.2k
Alexandra Gaenslen Germany	20	1.0k 1.1×	182 0.3×	285 0.7×	82 0.3×	278 1.1×	30	1.4k
Jesús Castro‐Marrero Spain	24	402 0.4×	1.1k 1.8×	170 0.4×	51 0.2×	121 0.5×	64	1.7k
Florian Wegner Germany	31	1.6k 1.7×	202 0.3×	891 2.0×	105 0.4×	344 1.4×	147	3.1k
George Hadjigeorgiou Greece	30	550 0.6×	373 0.6×	319 0.7×	45 0.2×	578 2.4×	61	2.5k

Countries citing papers authored by Paul Bergmans

Since Specialization

Citations

This map shows the geographic impact of Paul Bergmans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Bergmans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Bergmans more than expected).

Fields of papers citing papers by Paul Bergmans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Bergmans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Bergmans. The network helps show where Paul Bergmans may publish in the future.

Co-authorship network of co-authors of Paul Bergmans

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Bergmans. A scholar is included among the top collaborators of Paul Bergmans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Bergmans. Paul Bergmans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kuijk, Arno W. R. van, Michael T. Nurmohamed, Stefan Siebert, et al.. (2023). Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data. Lara D. Veeken. 62(10). 3382–3390. 14 indexed citations

Gossec, Laure, Elke Theander, Soumya D. Chakravarty, et al.. (2023). Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study. Arthritis Research & Therapy. 25(1). 100–100. 2 indexed citations

Gossec, Laure, Stefan Siebert, Paul Bergmans, et al.. (2023). Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. HAL (Le Centre pour la Communication Scientifique Directe). 1 indexed citations

Gossec, Laure, Stefan Siebert, Paul Bergmans, et al.. (2022). Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Annals of the Rheumatic Diseases. 81(6). 823–830. 21 indexed citations

Gossec, Laure, Stefan Siebert, Paul Bergmans, et al.. (2022). Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Annals of the Rheumatic Diseases. 82(4). 496–506. 16 indexed citations

Chung, Young‐Chul, et al.. (2022). Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting. Clinical Psychopharmacology and Neuroscience. 20(3). 427–439. 2 indexed citations

Smolen, Josef S, Stefan Siebert, Т. В. Коротаева, et al.. (2021). Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Annals of the Rheumatic Diseases. 80(11). 1419–1428. 22 indexed citations

Lencer, Rebekka, et al.. (2021). Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate. Comprehensive Psychiatry. 107. 152233–152233. 6 indexed citations

Paul, C., Giampiero Girolomoni, MA Radtke, et al.. (2015). Impact of Alexithymia and Disease Characteristics on Work Productivity and Activity In Psoriasis Patients With Short Disease Duration: Epidepso Multicentre Study. Value in Health. 18(7). A425–A426. 2 indexed citations

10.

Varannes, Stanislas Bruley des, Renzo Cestari, Κonstantinos Τriantafyllou, et al.. (2014). Classification of adults suffering from typical gastroesophageal reflux disease symptoms: contribution of latent class analysis in a European observational study. BMC Gastroenterology. 14(1). 112–112. 4 indexed citations

11.

Schreiner, A., Paul Bergmans, Sofia Keim, et al.. (2014). A Prospective Flexible-Dose Study of Paliperidone Palmitate in Nonacute But Symptomatic Patients With Schizophrenia Previously Unsuccessfully Treated With Oral Antipsychotic Agents. Clinical Therapeutics. 36(10). 1372–1388.e1. 31 indexed citations

12.

Schreiner, A., Dana Niehaus, Kaire Aadamsoo, et al.. (2012). Metabolic Effects of Paliperidone Extended Release Versus Oral Olanzapine in Patients With Schizophrenia. Journal of Clinical Psychopharmacology. 32(4). 449–457. 24 indexed citations

13.

Gäebel, Wolfgang, A. Schreiner, Paul Bergmans, et al.. (2010). Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial. Neuropsychopharmacology. 35(12). 2367–2377. 95 indexed citations

14.

Diener, Hans‐Christoph, R. Agosti, Gianni Allais, et al.. (2007). Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 6(12). 1054–1062. 108 indexed citations

15.

Boer, Wink de, Niek J. de Wit, Han Geldof, et al.. (2006). DoesHelicobacter pyloriinfection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole?. Scandinavian Journal of Gastroenterology. 41(10). 1147–1154. 5 indexed citations

16.

Berendse, Henk W., Jan Booij, Paul Bergmans, et al.. (2001). Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Annals of Neurology. 50(1). 34–41. 229 indexed citations

17.

Tissingh, Gerrit, Henk W. Berendse, Paul Bergmans, et al.. (2001). Loss of olfaction in de novo and treated Parkinson's disease: Possible implications for early diagnosis. Movement Disorders. 16(1). 41–46. 221 indexed citations

18.

Tissingh, Gerrit, Paul Bergmans, Jan Booij, et al.. (1997). [123I]β-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. European Journal of Nuclear Medicine and Molecular Imaging. 24(9). 1171–1174. 28 indexed citations

19.

Wolters, Erik Ch., Gerrit Tissingh, Paul Bergmans, & Michaël Kuiper. (1995). Dopamine agonists in Parkinson's disease. Neurology. 45(3_suppl_3). S28–34. 48 indexed citations

20.

Kuiper, Michaël, Jelle Visser, Paul Bergmans, Philip Scheltens, & Erik Ch. Wolters. (1994). Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. Journal of the Neurological Sciences. 121(1). 46–49. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact